Table 2.
Substrate | Mutant | Km (μM) | Vmax (pmol/mg/min) |
---|---|---|---|
E17βG | WT | 5.35 ± 0.54 | 228 ± 19.8 |
R57A | 30.5 ± 3.64 * | 319 ± 50.6 | |
R57K | 8.62 ± 0.33 * | 152 ± 31.3 | |
K361A | 14.5 ± 2.02 * | 178 ± 36.0 | |
K361R | 11.9 ± 2.57 * | 224 ± 24.3 | |
E3S | WT | 0.55 ± 0.12 | 38.6 ± 5.81 |
R57A | 0.81 ± 0.03 | 30.2 ± 5.53 | |
R57K | 0.96 ± 0.21 | 22.4 ± 3.64 | |
K361A | 0.54 ± 0.07 | 11.34 ± 2.95 * | |
K361R | 1.83 ± 0.33 * | 23.9 ± 5.90 | |
BSP | WT | 0.46 ± 0.04 | 52.2 ± 9.42 |
R57A | 0.69 ± 0.04 * | 38.5 ± 4.69 | |
R57K | 0.40 ± 0.04 | 38.3 ± 4.34 | |
K361A | 0.97 ± 0.14 * | 52.4 ± 17.6 | |
K361R | 1.05 ± 0.15 * | 51.7 ± 23.7 |
Kinetic parameters of wild type and mutated OATP1B1-mediated E17βG (estradiol-17β-glucuronide), E3S (estrone-3-sulfate) and BSP (bromosulfophthalein) uptake were measured under initial linear rate conditions, corrected for surface expression and presented as mean ± SE of 3 to 13 independent experiments. Uptake of E17βG (1 μM to 50 μM) and BSP (0.05 μM to 3 μM) was measured at 37°C for 1 minute; uptake of E3S (0.05 μM to 2 μM) was measured at 37°C for 30 seconds;
p < 0.05.